SUMO2/3 Antibody (SPM572), DyLight 350, Novus Biologicals™

SUMO2/3

Monoclonal

DyLight 350

SUMO2

Recombinant human SUMO2 protein

0.1 mL

Apoptosis

6613

Human

Purified

Western Blot, Flow Cytometry, ELISA, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin)

SPM572

Western Blot, Flow Cytometry, ELISA, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin, Immunohistochemistry-Frozen

Mouse

Protein A or G purified

RUO

Primary

This monoclonal antibody reacts with both SUMO-2 and SUMO-3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1

Store at 4C in the dark.

IgG1 κ